Evercare, Leading Healthcare Platform, Appoints New CEO

Evercare, a healthcare delivery platform that operates hospitals, clinics and diagnostic facilities across Africa and South Asia, today announced the appointment of Massimiliano (Max) Colella as Chief Executive Officer, effective January 1, 2020. Mr. Colella will continue to strengthen Evercare’s leadership position by driving growth and operational excellence at existing facilities, leveraging technology to improve the delivery and cost of healthcare, bringing projects in development to market, and searching for new and complementary investments.

“Throughout my nearly three decades of working in the healthcare industry in Africa, Asia and the Middle East, I have seen first-hand what is needed to build strong healthcare systems in these regions. I look forward to leveraging that experience to help strengthen Evercare’s leadership position, with the ultimate goal of reaching more patients with the highest quality care,” said Mr. Colella.

Evercare is wholly owned by The Evercare Health Fund, a $1B emerging markets healthcare fund managed by The Rise Fund, the impact investment platform of global alternative asset manager TPG. The Evercare Health Fund is comprised of the world’s leading development finance institutions and other impact investors.

Matthew Hobart, Co-Managing Partner of TPG Growth and head of healthcare investing for The Rise Fund, said, “There is an urgent need to expand the delivery of affordable high-quality healthcare across the emerging markets. We are excited to have Max joining the Evercare leadership team and believe his extensive expertise in scaling global healthcare businesses will meaningfully advance Evercare’s mission.”

Mr. Colella has over 27 years of experience in the medical device industry. He joins Evercare from Smith & Nephew, a leading medical technology company, where he was President of Europe, Middle East, and Africa, and previously served as Senior Vice President of Asia Pacific and Emerging Markets.

Prior to that, Mr. Colella spent 21 years at Johnson & Johnson in a number of national and international roles in Europe and Emerging Markets within the Ethicon and DePuy Synthes franchises. – Business Wire